More than a billion people suffer from vision impairments. Cataracts, and the surgery to correct them, is one of the most common surgical procedures in the world. Even though the surgery is relatively easy, there aren't enough surgeons and not enough money to pay them. The $55 million Series A raised by ForSight will be used to continue the development of its surgery robot. Around 18 months after its seed round, the round comes.

The Oryom platform is a surgery robot. It uses cutting-edge technologies in surgery. The platform wants to automate surgeries that treat diseases that can lead to blind spots. The company claims to be 10 times more accurate than the human hand with the help of robotic technology.

"We are excited to be able to advance our technology with this investment to bring robotics into the world of ophthalmic surgery to help millions of patients who have to wait unnecessarily for procedures while their eyesight degrades," says Daniel Glozman, CEO and co- founder. Our goal is to make this procedure more accessible to patients around the world.

High income countries have more eye surgeons per million people than low income countries. Many causes of blindness could be prevented by the surgeries. The funds raised will be used to speed up the development of the platform in clinical trials, with the ultimate goal of benefiting as many patients as possible. The company is expanding its technical team and is actively hiring impact-driven engineers in the mechanical, software and hardware fields.